BRIEF published on 04/23/2025 at 20:35, 1 year 6 months ago GenSight Biologics Announces Annual General Meeting Details Annual General Meeting Shareholders Gene Therapy GenSight Biologics Retinal Diseases
PRESS RELEASE published on 04/23/2025 at 20:30, 1 year 6 months ago Inside Information / Other news releases GenSight Biologics to hold Annual General Meeting on May 13, 2025 at 2:00 pm CEST in Paris, France. Procedures for obtaining preparatory documents outlined Annual General Meeting Preparatory Documents GenSight Biologics Gene Therapies Retinal Diseases
BRIEF published on 04/08/2025 at 07:51, 1 year 7 months ago GenSight Biologics Files its 2024 Universal Registration Document AMF Gene Therapy Registration Document GenSight Biologics Retina
BRIEF published on 04/08/2025 at 07:48, 1 year 7 months ago GenSight Biologics Files 2024 Universal Registration Document Universal Registration Document GenSight Biologics Gene Therapies Retinal Diseases Financial Report 2024
PRESS RELEASE published on 04/08/2025 at 07:43, 1 year 7 months ago INSIDE INFORMATION / OTHER NEWS RELEASES GenSight Biologics announces the filing of its 2024 Universal Registration Document with the French market authority, including financial reports and corporate governance details GenSight Biologics Gene Therapies Retinal Neurodegenerative Diseases 2024 Universal Registration Document Central Nervous System Disorders
BRIEF published on 04/07/2025 at 20:19, 1 year 7 months ago GenSight Biologics Financial and Business Update Fundraising Clinical Trials Gene Therapy Financial Update GenSight Biologics
PRESS RELEASE published on 04/07/2025 at 20:14, 1 year 7 months ago Inside Information / News release on accounts, results GenSight Biologics reports cash position and business update as of March 31, 2025. Discussions with French agency progressing. Fundraising planned for Phase III trial and marketing advancement Business Update Cash Position Fundraising Activities GenSight Biologics RECOVER Phase III Trial
BRIEF published on 03/17/2025 at 07:35, 1 year 7 months ago GenSight Biologics Presents LUMEVOQ® at NANOS 2025 Gene Therapy GenSight Biologics LUMEVOQ® NOHL NANOS Congress
PRESS RELEASE published on 03/17/2025 at 07:30, 1 year 7 months ago Inside Information / Other news releases GenSight Biologics will present scientific updates on LUMEVOQ gene therapy at NANOS 2025, including real-world experience and long-term outcomes for LHON treatment Gene Therapy GenSight Biologics LHON LUMEVOQ NANOS 2025
BRIEF published on 03/07/2025 at 08:34, 1 year 8 months ago GenSight Biologics Secures €0.9 Million Financing from Existing Investors Investors Financing Gene Therapy GenSight Biologics Retinal Diseases
Published on 11/14/2026 at 12:56, 3 hours 11 minutes ago Gabriel Announces Dismissal of ICSID Annulment Application
Published on 11/14/2026 at 01:30, 14 hours 37 minutes ago NuRAN Wireless Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency
Published on 11/14/2026 at 00:40, 15 hours 27 minutes ago BEACN Announces Annual General and Special Meeting Results
Published on 11/14/2026 at 00:35, 15 hours 32 minutes ago American Hotel Income Properties REIT LP Reports Q3 2026 Results
Published on 11/14/2026 at 00:00, 16 hours 7 minutes ago SLAM Announces Proposed Extension of Warrant Expiry Dates
Published on 11/13/2026 at 23:24, 16 hours 43 minutes ago EQS-Adhoc: ASOS PLC: Repurchase of £90m of 2028 Convertible Bonds
Published on 11/13/2026 at 21:52, 18 hours 15 minutes ago EQS-Adhoc: Airbus reports share buyback transactions 9-13 November 2026
Published on 11/13/2026 at 19:08, 20 hours 58 minutes ago EQS-Adhoc: CHAPTERS Group AG: Successful Completion of Private Placement of the Capital Increase from Authorized Capital Resolved on November 13, 2026
Published on 11/13/2026 at 18:04, 22 hours 3 minutes ago EQS-Adhoc: CHAPTERS Group AG: Capital Increase from Authorized Capital Resolved
Published on 11/13/2026 at 11:35, 1 day 4 hours ago ENGIE and Google to partner on energy solutions for a potential data center project near Châteauroux, France
Published on 11/12/2026 at 23:12, 1 day 16 hours ago Belgrano continues the implementation of its public share buyback offer (OPRA)
Published on 11/12/2026 at 18:36, 1 day 21 hours ago AXA: Information relating to the number of voting rights and shares making up the share capital on 31/10/2026
Published on 11/12/2026 at 18:00, 1 day 22 hours ago Information concerning the total number of voting rights and shares in the share capital as of November 12, 2026
Published on 11/12/2026 at 17:40, 1 day 22 hours ago Financial information for the period ended 30 September 2026
